We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+21.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$631M
AUM Growth
+$110M
Cap. Flow
+$37M
Cap. Flow %
5.86%
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17M
2
GKOS icon
Glaukos
GKOS
+$9.15M
3
BIIB icon
Biogen
BIIB
+$9.05M
4
ELGX
Endologix Inc
ELGX
+$6.78M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.67M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.1M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$11.1M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$5.44M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.39M
5
CNC icon
Centene
CNC
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 92%
2 Financials 1.18%
3 Technology 0.15%
4 Energy 0.12%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$317B
$10.2M 1.61%
167,680
+94,320
+129% +$5.72M
CI icon
27
Cigna
CI
$74.6B
$9.38M 1.48%
64,000
-5,000
-7% -$737K
HCA icon
28
HCA Healthcare
HCA
$89.5B
$9.32M 1.48%
104,707
– –
JAZZ icon
29
Jazz Pharmaceuticals
JAZZ
$16.7B
$8.75M 1.39%
60,320
+9,400
+18% +$1.22M
KITE
30
DELISTED
Kite Pharma, Inc.
KITE
$8.63M 1.37%
110,000
+30,000
+38% +$1.86M
ZBH icon
31
Zimmer Biomet
ZBH
$18.4B
$8.55M 1.35%
72,100
-10,300
-13% -$1.17M
ABBV icon
32
AbbVie
ABBV
$434B
$8.47M 1.34%
130,000
+15,000
+13% +$943K
ALKS icon
33
Alkermes
ALKS
$8.25B
$8.21M 1.3%
140,409
+64,810
+86% +$3.68M
SUPN icon
34
Supernus Pharmaceuticals
SUPN
$2.77B
$7.2M 1.14%
230,000
-20,000
-8% -$536K
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$29.3B
$6.66M 1.06%
130,000
-5,000
-4% -$231K
AET
36
DELISTED
Aetna Inc
AET
$6.63M 1.05%
52,000
-10,000
-16% -$1.26M
HUM icon
37
Humana
HUM
$46.2B
$6.6M 1.04%
32,000
-8,000
-20% -$1.65M
HOLX
38
DELISTED
Hologic
HOLX
$6.38M 1.01%
150,000
-10,000
-6% -$408K
ESRX
39
DELISTED
Express Scripts Holding Company
ESRX
$6.33M 1%
96,000
-15,000
-14% -$1.03M
CNC icon
40
Centene
CNC
$32.5B
$6.24M 0.99%
175,186
-124,814
-42% -$4.18M
XNCR icon
41
Xencor
XNCR
$1.55B
$6.22M 0.98%
260,000
+35,000
+16% +$843K
ELV icon
42
Elevance Health
ELV
$85.5B
$6.2M 0.98%
37,468
-20,789
-36% -$3.31M
TMO icon
43
Thermo Fisher Scientific
TMO
$220B
$6.14M 0.97%
40,000
-5,000
-11% -$764K
CAH icon
44
Cardinal Health
CAH
$55.4B
$6.12M 0.97%
75,000
+10,000
+15% +$787K
DVAX
45
DELISTED
Dynavax Technologies
DVAX
$5.86M 0.93%
984,696
+499,696
+103% +$2.4M
EW icon
46
Edwards Lifesciences
EW
$51.7B
$5.64M 0.89%
180,000
-30,000
-14% -$939K
COR icon
47
Cencora
COR
$61.2B
$5.58M 0.88%
63,000
-5,000
-7% -$439K
SAGE
48
DELISTED
Sage Therapeutics
SAGE
$5.16M 0.82%
+72,659
New +$4.26M
ABT icon
49
Abbott
ABT
$187B
$5.11M 0.81%
+115,000
New +$4.97M
IOVA icon
50
Iovance Biotherapeutics
IOVA
$2.83B
$4.84M 0.77%
650,000
– –
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rhenman & Partners Asset Management held 113 positions worth $631M, up 21% from $522M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management deployed $37M of net new capital in Q1 2017, opening 5 new positions and adding to 44 existing holdings. Its largest new stake was Abbott: 115,000 shares worth $5.11M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $4.39M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2017 buy was Abbott: 115,000 shares worth $5.11M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $17M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2017 reduction was Bristol-Myers Squibb, cutting an estimated $4.39M.
  • Rhenman & Partners Asset Management fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $13.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $631M portfolio in Q1 2017.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 9 in Q1 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 21% quarter-over-quarter to $631M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.